BrainsWay (ADR) Logo
US10501L1061
A2PCBP
BWAY

BrainsWay (ADR)

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 17,73 € (+108,34 %). La mediana es de 17,73 € (+108,34 %).

Comprar
  7
Mantener
  1
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • BrainsWay beats revenue forecasts in Q2 2026 and raises full-year outlook

    BrainsWay reported revenue of $17.1 million in Q2 2026, beating analysts’ estimate of $16.31 million; adjusted earnings per share were $0.07, in line with expectations. The company raised its 2026 revenue guidance to $68–70 million and recorded revenue growth of 35% year over year along with more than a fourfold increase in operating income. Gross margin remained steady at 75%, adjusted EBITDA was positive for the twelfth consecutive quarter, and the installed system base rose to around 1,950 units. Management cites strong demand for Deep TMS and the SWIFT protocol, as well as reimbursements covering about 57 million insured people, as drivers. » Más en de.investing.com


  • BrainsWay invests $3 million in Radial Health

    BrainsWay has acquired a $3 million minority stake in Radial Health as part of a Series A financing round. Radial operates a network of brain-medicine clinics and develops clinical infrastructure, reimbursement tools, and an AI-supported decision platform for non-invasive therapies such as Deep TMS. The capital will be used to expand clinical presence, strengthen the technology platform and evaluate M&A opportunities; BrainsWay describes the investment as part of a strategy to acquire minority stakes in mental health care providers. » Más en de.investing.com


  • BrainsWay: US insurers allow psychiatric nurse practitioners to provide TMS treatment

    A growing number of US insurers, including Optum/United Behavioral Health, have allowed psychiatric nurse practitioners in full-practice states since the end of 2025 to prescribe, supervise and administer transcranial magnetic stimulation (TMS) for commercial plans covering about 34.8 million enrollees. Other payers and providers such as First Coast, National Government Services, Novitas, the VA and TRICARE West have introduced similar reimbursement models, subject to regulatory requirements. BrainsWay sees this as an opportunity to improve access to deep TMS and shorten waiting times; the stock reacted positively and is trading near its 52-week high after a 258% gain last year. » Más en de.investing.com


  • BrainsWay invests additional $6 million in Neurolief after FDA premarket clearance

    BrainsWay closes a milestone-based convertible note of $6 million as a second tranche for Neurolief after Neurolief received FDA premarket clearance for the Proliv™Rx system. With this, BrainsWay has invested a total of $11 million in Neurolief; a third tranche of up to $5 million is possible if a revenue-based target is met. BrainsWay also holds a purchase option on all outstanding shares of Neurolief, with the price tied to a fixed company valuation or a revenue multiple. Parallel to the financing, Neurolief is expanding provider access by adding an authorized distributor to the U.S. Department of Veterans Affairs supplier list. » Más en de.investing.com


  • BrainsWay: Highmark plans expanded reimbursement for accelerated Deep‑TMS protocol

    Highmark Blue Cross Blue Shield has issued a draft policy to expand reimbursement for BrainsWay’s accelerated SWIFT‑Deep‑TMS protocol for adolescents and adults with major depressive disorder. After a public comment period, the rule is expected to take effect in February 2026 and covers a five‑times‑daily, 10‑minute program over six days plus follow‑up sessions (38 sessions in total). The FDA approved the protocol in September 2025; data showed a response rate of 87.8% and a remission rate of 78.0%, prompting BrainsWay to anticipate broader market acceptance. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, BrainsWay (ADR) tuvo unos ingresos de 15,89 M € y un beneficio neto de 1,95 M €
(EUR) septiembre de 2026
YoY
Ingresos 15,89 M 37,99 %
Beneficio bruto 12,38 M 42,96 %
Beneficio neto 1,95 M 45,79 %
EBITDA 2,68 M 13,12 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
360,6 M €
Número de acciones
39,22 M
Máximo/mínimo de 52 semanas
15,82 € - 4,58 €
Dividendos No
Beta
0,15
Ratio P/E
38,94
Ratio PEG
0,62
Ratio P/B
4,90
Ratio P/S
5,83

Perfil de la empresa

Brainsway Ltd. desarrolla y comercializa tratamientos de neuroestimulación no invasiva para trastornos de salud mental en Estados Unidos, Europa, Israel y a nivel internacional. Ofrece la tecnología de su plataforma de estimulación magnética transcraneal profunda (Deep TMS) para el tratamiento de trastornos depresivos mayores, depresión ansiosa, trastornos obsesivo-compulsivos, adicción al tabaco, trastornos bipolares, trastorno de estrés postraumático, esquizofrenia, enfermedad de Alzheimer, autismo, dolor crónico, esclerosis múltiple, rehabilitación tras un ictus y enfermedad de Parkinson. La empresa atiende principalmente a médicos, hospitales y centros médicos en el campo de la psiquiatría. Brainsway Ltd. fue fundada en 2003 y tiene su sede en Jerusalén, Israel.

Nombre
BrainsWay (ADR)
CEO
Hadar Levy
Sede Jerusalem, jm
Israel
Sitio web
Sector
Salud
Industria
Equipos y suministros sanitarios
Salida a bolsa
17/12/2018
Empleados 129

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
BWAY
🍪

Parqet  usa cookies. Más información